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Summary Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000-mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR, 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or nodal metastasis. Three PRs were obtained in patients resistant to 5-fluorouracil. The difference in survival between patients who achieved PR and those who had a stabilisatiot was not statistically significant. On the other hand the survival of patients with PR was significantly longer than that of patients who progressed. Oral TG was well tolerated by most patients. WHO grade 1-2 gastrointestinal and neurological toxicities were seen respectively in 36% and 25% of cases. Five patients had grade 3 nausea/vomiting and one had grade 3 diarrhoea. Our data suggest that oral TG is effective in the treatment of stomach and colorectal cancers.
The fluoropyrimidines are among the most active classes of anti-neoplastic agents employed in the treament of gastrointestinal tract cancers (GTC). 5-Fluorouracil (5-FU), which is the most widely used fluoropyrimidine anti-metabolite, has been shown to yield a 15-30% overall response rate in advanced and/or metastatic gastrointestinal carcinomas (Carter, 1976; Comis & Carter, 1974; Carter & Comis, 1976) . Although 5-FU is rather active in these tumours, repeated administration of 5-FU is often associated with a significant and sometime severe gastrointestinal and haematological toxicity (Friedman & Ignoffo, 1980) . Tegafur (TG), a tetradhydro-2-furanyl derivative of 5-fluorouracil, has been reported to be effective by the intravenous route against GTC yielding an 11-25% overall response rate (Blokhina et al., 1972; Buroker et al., 1977; Schutt et al., 1983) . TG, administered intravenously, causes a significant and doserelated neurological toxicity in 15-70% of patients due to its ability to cross easily the blood-brain barrier (Friedman & Ignoffo, 1980; Bedikian et al., 1983) . Butyrolactone, a metabolite produced during TG activation, is thought to be partly responsible for neurotoxicity (Au & Sadee, 1980) . Neurological side-effects have been the dose-limiting toxicity in about one-third of patients receiving intravenous TG (Carter & Slavik, 1976; Friedman & Ignoffo, 1980) . TG is also well absorbed after oral administration, and it has been reported to yield a 20% overall response rate in GTC. It is also less toxic than 5-FU and TG given intravenously (Bedikian et al., 1983) . TG is considered to be a pro-drug of 5-FU and it exerts its activity, at least in part, after conversion to 5-FU (Benvenuto et al., 1978; Diasio et al., 1979; Van Putten et al., 1979) . After oral administration of TG, the plasma concentration of 5-FU and the cumulative areas under the concentration versus time curve have been reported to be comparable to those obtained after a 5-day continuous infusion of 5-FU (Schilcher et al., 1983) . However, other authors reported that following TG administration, serum 5-FU levels have been found to be extremely low (often undetectable), suggesting that TG is converted intracellularly to 5-FU which may not be redistributed into the circulation before further metabolisation Hornbeck et al., 1981) . Oral TG, at the dose of 1,000-1,500 mg m2 day-', causes moderate neurological and gastrointestinal toxicity in about 10-20% of patients, thus showing that the oral route is more suitable for clinical purposes than the intravenous administration (Dindogru et al., 1980; Hunter & Browder, 1980 (n = 5) , gall bladder carcinoma (n = 3) and epatocarcinoma (n = 3), while four PR (33%) were obtained in gastric carcinoma (n = 12). Out of 18 patients with colorectal carcinoma three (17%) achieved PR, two patients (11%) MR, six NC (33%) and seven patients (39%) progressed. Out of 10 patients previously treated with 5-FU containing regimens, three patients (30%) achieved an objective response (PR), three (30%) did not progress (NC) and four (40%) showed no response.
The impact of tegafur therapy on survival is shown in Table II and Figure 1 . Patients who had PR (median survival 26.8 weeks) did not survive longer than patients who had a stabilisation of their disease (median 53.5 weeks). The difference in median survival between patients who responded (PR + MR) and those who progressed (median survival 10.8 weeks) is statistically significant (P <0.001).
Out of 50 enrolled patients, 44 (88%) were evaluable for toxicity. Toxic effects of oral TG according to WHO criteria are shown in Table IV . During a total of 161 complete cycles administered, the most frequent side-effects were: grade 1-3 nausea/vomiting in 48% of patients (only one case of grade 3), and grade 1-2 neurological toxicity in 25% of cases, mainly in the form of dizziness, headache, insomnia and lethargy. Neurological toxicity was generally mild and in no case was it dose-limiting. No renal and cardiac toxicities were seen. Clinical studies have demonstrated that TG exert an antineoplastic activity comparable to that of 5-FU against several tumours, including gastrointestinal and breast carcinomas (Buroker et al., 1977; Friedman & Ignoffo, 1980; Schutt et al., 1983) . Full dose infusion of TG is often associated with severe gastrointestinal and neurological toxicity, which makes the drug unsuitable for repeated intravenous administration. TG, however, is reliably absorbed by the gastrointestinal tract and low dose oral therapy for 14-21 consecutive days minimises the toxic effects seen after infusion (Friedman & Ignoffo, 1980; Hunter & Browder, 1980; Bedikian et al., 1983) .
We treated 50 consecutive patients affected by advanced and/or metastatic gastrointestinal tract cancer (GTC) with oral TG 1,000 mg m-2 on days 1-14. This regimen was repeated every 28 days or until toxicity recovered. The treatment was generally well tolerated. Mild neurological and gastrointestinal toxicities were seen respectively in 25% and 48% of patients. Seventeen per cent of 42 evaluable patients achieved a partial response, 7% had a minor response, 21% showed a stabilisation of disease and 55% of patients progressed. This overall response rate confirms our preliminary results (Palmeri et al., 1986) and is within the range of activity reported by other authors for oral TG (Browder et al., 1979; Stroehlein et al., 1981; Ansfeld et al., 1983; Brenner et al., 1989 (1980) , reporting an objective response in 50% of patients pretreated with 5-FU and progressed thereafter. However, these data are not confirmed by experimental studies which demonstrated cross-resistance of TG and 5-FU in mice bearing L1210 lymphocytic leukaemia (Garibjarian et al., 1976) . Initial pharmacological studies showed that TG is a pro-drug of 5-FU for it is slowly metabolised in the liver by microsomal enzymes to 5-FU (Belitsky et al., 1981) . 5-FU is in turn slowly released into the systemic circulation where it reaches detectable levels for a prolonged period of time (Garibjanian et al., 1976; Benvenuto et al., 1978; Schilcher et al., 1983) . However, other reports have demonstrated that 5-FU plasma concentrations after TG administration are almost undetectable and considerably below those observed after an equivalent intravenous dose of 5-FU Hornbeck et al., 1981) . It seems likely that TG is intracellularly converted to 5-FU which is further metabolised before redistribution. As reported by , alternative routes of intracellular activation of TG to 5-FU with the production of active metabolites cannot be excluded at present. Moreover intracellularly formed 5-FU may be further metabolised without being redistributed through the circulation .
Statistical analysis failed to show any significant difference in survival between patients who enjoyed PR and those who had a stabilisation. On the other hand, patients who had PR survived longer than those who progressed (P <0.001).
In conclusion our data suggest that oral therapy with TG is an active treatment for advanced and/or metastatic gastric and colorectal carcinomas with mild gastrointestinal and neurological toxicity, but without a striking positive impact on survival. No activity was seen in cancers arising from hepatobiliary system and pancreas. Although data concerning the lack of cross-resistance between 5-FU and TG are not conclusive, we feel that oral TG, alone or in combination with other drugs, may represent a useful drug in the palliative treatment of gastric and colorectal carcinomas. The employment of TG in cases pretreated with 5-FU is still a matter of debate.
